MWM
CRSP icon

Moran Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Moran Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.93M Buy
35,374
+10,072
+40% +$531K 0.05% 330
2026
Q1 		$1.2M Buy
25,302
+8,717
+53% +$460K 0.04% 345
2025
Q4 		$870K Sell
16,585
-5,112
-24% -$306K 0.03% 367
2025
Q3 		$1.41M Buy
21,697
+8,043
+59% +$462K 0.04% 311
2025
Q2 		$664K Buy
+13,654
New +$528K 0.02% 366

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Moran Wealth Management's CRSP Position: Q2 2026 in Review

Moran Wealth Management increased its CRISPR Therapeutics (CRSP) stake by 40% in Q2 2026, buying an estimated $531K and bringing the position to 35,374 shares worth $1.93M. The position accounts for 0.05% of the portfolio, ranked #330.

Moran Wealth Management first reported a position in CRSP in Q2 2025 and has held it in 5 quarters since. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Moran Wealth Management held 35,374 shares of CRISPR Therapeutics worth $1.93M as of Q2 2026.
  • Moran Wealth Management bought 10,072 CRISPR Therapeutics shares in Q2 2026, an estimated $531K.
  • CRISPR Therapeutics made up 0.05% of Moran Wealth Management's portfolio in Q2 2026, its #330 holding.
  • Moran Wealth Management first reported a position in CRISPR Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Moran Wealth Management's 13F filing for Q2 2026, filed 5 Aug 2026.